一种DNA介导的溶酶体降解策略,用于PD-L1蛋白的有针对性的降解
Wenjing Huang1, Can Yang1, Sizhu Cheng1
1School of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai 200444, P. R. China.
一种新型的双功能化合物,PBL1,准食尸受体,在癌细胞中降解PD-L1. 这种方法减少了非目标毒性,提供了更安全的癌症免疫疗法替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 编程细胞死亡配体1 (PD-L1) 表达允许瘤逃避T细胞免疫监测.
- PD-L1细胞表面水平对于PD-L1向免疫检查点阻塞疗法的有效性至关重要.
研究的目的:
- 开发一种用于PD-L1降解的新策略,使用清理受体 (SRs) 来增强癌症免疫疗法.
- 为了创建一个双功能化合物,针对SRs和PD-L1进行 lysosomal 降解.
主要方法:
- 利用点击化学,将PD-L1抑制剂BMS-202与树状DNA支架结合在一起,形成双功能化合物PBL1.1.
- 使用SRs的贩运能力将PD-L1引导到溶酶体中进行降解.
- 在A549细胞和斑马鱼模型中验证了PBL1的疗效和特异性.
主要成果:
- 在体外和体内,PBL1有效诱导PD-L1降解.
- 与传统PD-L1抑制剂相比,显著降低了目标外毒性.
- 在细胞和动物模型中证明了PBL1的疗效和特异性.
结论:
- 通过SRs介导的PD-L1 lysosomal降解是癌症免疫治疗的一个有希望的策略.
- PBL1提供了一个比现有的PD-L1抑制剂更安全,更有针对性的替代品.
- 这种方法增强了免疫检查点阻塞疗法的潜力.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
相关概念视频
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Lysosomal Hydrolases
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Intrinsic Apoptotic Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
